Regeneron files an RA antibody for FDA approval; Dimension leases a new R&D hub;

@FierceBiotech: Biogen spells out its moonshot R&D strategy amid deep cost cuts. More | Follow @FierceBiotech

@JohnCFierce: Oxford team spotlights promise of AstraZeneca drug in targeting cancers. FierceBiotechResearch article | Follow @JohnCFierce

> Regeneron Pharmaceuticals ($REGN) has filed sarilumab, an antibody for rheumatoid arthritis, for FDA approval. More

> Allergan ($ACT) paid an undisclosed sum for Northwood Medical Innovation to get its hands on a CE-marked aesthetic device to correct prominent ears. News

> Dimension Therapeutics ($DMTX) has leased a 17,475-square-foot R&D outpost in Woburn, MA. Item

Medical Device News

@FierceMedDev: Roche launches rapid HIV, hep C tests in Europe. Article | Follow @FierceMedDev

@VarunSaxena2: Medtronic releases health economics study of its drug-coated balloon at Las Vegas conference. Story | Follow @VarunSaxena2

@EmilyWFierce: Does AstraZeneca own the color purple? On a pill, yes, the company contends. FiercePharmaMarketing story | Follow @EmilyWFierce

> Theranos CEO heeds call for transparency for proprietary technology. Article

> Medtronic axes 150 jobs in new Irish tax domicile. News

Pharma News

@FiercePharma: GSK's vaccine unit sees revenue, profit jump in Q3. More from FierceVaccines | Follow @FiercePharma

@CarlyHFierce: Good thing Bayer's in Germany, CEO says. U.S. business culture is too impatient. Story | Follow @CarlyHFierce

> McCaskill turns up heat on Valeant with Senate pricing probe. Story

> Novo adding 450 more Denmark jobs as its bets on growth in insulin demand. Article

Pharma Marketing News

> GlaxoSmithKline's HIV bright spot could get brighter with new Tivicay combo meds. Item

> Viewers skeptical of DTC ads, but they drive people to docs anyway. More

> Bristol-Myers Q3 ad spending pushes up to $193M on renewed promotions push. Story

> Pfizer launches first Prevnar TV spot to bring in the 50-plus crowd. Report

> Does AstraZeneca own the color purple? On a pill, yes, the company contends. Article

Biotech Research News

> Neat 'trick' guards peptides against early degradation. Story

> JAK inhibitors target senescent cells in aging study. Item

> Small molecule used to blunt glioblastoma growth in mice--UCSD. More

> Researchers devise heat-triggered liposome 'grenades' to destroy cancer cells. Story

> UPenn researchers show importance of calcium signaling for Ebola virus. Article

Vaccines News

> Takeda, Hilleman eye low-cost vaccine space. News

> Sanofi expects first dengue vaccine license in Q4. Item

> Pfizer teams up with the Biovac Institute to produce Prevenar 13 in South Africa. Report

> GSK's vaccine unit sees revenue, profit jump in Q3. Story

> European Commission launches €23M HIV vaccine research initiative. Article

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

NYC’s outstanding talent and funding, the city is rich with life science real estate offerings across the five boroughs.

Sutro Biopharma’s lead antibody-drug conjugate shrank tumors in 13% of patients with ovarian cancer who had tried a median of six other treatments.

Immuno-oncology biotech Silverback Therapeutics has more than doubled its original IPO hopes.